Antibacterial Spectrum of a Tetrazole-Based Reversible Inhibitor of Serine beta-Lactamases.
Pemberton, O.A., Zhang, X., Nichols, D.A., DeFrees, K., Jaishankar, P., Bonnet, R., Adams, J., Shaw, L.N., Renslo, A.R., Chen, Y.(2018) Antimicrob Agents Chemother 62
- PubMed: 29844038 
- DOI: https://doi.org/10.1128/AAC.02563-17
- Primary Citation of Related Structures:  
6BT6, 6BU3 - PubMed Abstract: 
CTX-M is the most prevalent family of extended-spectrum β-lactamases. We recently developed a tetrazole-derived noncovalent inhibitor of CTX-M-9. Here, we present the biochemical and microbiological activity of this inhibitor across a representative panel of serine β-lactamases and Gram-negative bacteria. The compound displayed significant activity against all major subgroups of CTX-M, including CTX-M-15, while it exhibited some low-level inhibition of other serine β-lactamases. Complex crystal structures with the CTX-M-14 S237A mutant and CTX-M-27 illustrate the binding contribution of specific active-site residues on the β3 strand. In vitro pharmacokinetic studies revealed drug-like properties and positive prospects for further optimization. These studies suggest that tetrazole-based compounds can provide novel chemotypes for future serine β-lactamase inhibitor discovery.
Organizational Affiliation: 
Department of Molecular Medicine, University of South Florida, Tampa, Florida, USA.